ArticleJournal of natural medicines2026
Anti-asthmatic effects and ingredient annotation of the active fraction from Ganoderma lucidum.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This research aims to screen the active fraction and explore the action mechanism of Ganoderma lucidum to combat asthma using asthmatic mice induced by OVA. In this study, three Ganoderma lucidum fractions, including GLEF40, GLEF60, and GLEF100, were obtained through the separation of D101 macroporous adsorption resin. The result of the anti-asthmatic effects illustrated that GLEFs significantly reduce Th2- and Th1- cytokines, together with chemokines MIP-1α and MDC in bronchoalveolar lavage fluid (BALF) in asthmatic mice. Among the three fractions, GLEF100 demonstrated the most potent anti-inflammatory effect. Besides, GLEF100 significantly reduced IgE levels in asthmatic mice (P < 0.001). Further analysis found that GLEF100 significantly reduced Myd88 protein levels and strongly inhibits the expression of phosphorylated ERK, phosphorylated JNK and NF-κB p65. To further explore the Anti-asthmatic active component Ganoderma lucidum, a total of 92 chemical components from GLE100 was annotated using the HPLC–Q-TOF–MS/MS. In conclusion, GLEF100 effectively relieving asthma symptoms by inducing balanced Th1/Th2 immunity and inhibiting TLR4/Myd88-NF-κB-MAPKs signaling pathway. These findings highlight the potential anti-asthmatic effects of GLEF 100 and lay the foundation for further identification of the anti-asthmatic active components of Ganoderma lucidum.
Indexed as
Identifiers
41886154What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.